Clinical trial
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and…
NCT00486759 · Hoffmann-La Roche, Industry · Terminated
Key facts
| NCT number | NCT00486759 |
|---|---|
| Title | A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma |
| Official title | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial Comparing the Efficacy of Bevacizumab in Combination With Rituximab and CHOP (R-CHOP + Bevacizumab) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL) |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Collaborators | Genentech, Inc. Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | B-cell Lymphoma |
| Intervention type | Drug |
| Interventions | Bevacizumab, Rituximab, CHOP, Placebo |
| Enrollment | 787 |
| Start date | Jul 26, 2007 |
| Primary completion | Nov 30, 2011 |
| Completion | Nov 30, 2011 |
| First posted | Jun 15, 2007 |
| Last update posted | Jul 25, 2017 |
| Countries | Argentina, Australia, Austria, Brazil, Canada, China, Colombia, Czechia, Ecuador, France, Germany, Greece and 22 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: